Literature DB >> 1324767

Spinal mechanisms of delta 9-tetrahydrocannabinol-induced analgesia.

P B Smith1, B R Martin.   

Abstract

Cannabinoids have been demonstrated to be effective antinociceptive agents when given intravenously. In order to determine whether spinal antinociception can be achieved while minimizing psychotomimetic properties, the pharmacological activity of delta 9-tetrahydrocannabinol (THC) was evaluated after intrathecal injection in male ICR mice. Although delta 9-THC produced potent antinociception, it also caused hypoactivity, hypothermia, and catalepsy. Intrathecal administration of delta 9-THC in mice which had their spinal cord transected at T12 also produced potent antinociception suggesting a spinal component to the antinociceptive effect. Biodispositional studies of [3H]delta 9-THC demonstrated that brain levels of the drug following intrathecal injection in spinally transected animals were not sufficient to produce the antinociceptive effect. These studies suggest the involvement of a spinal component in the antinociceptive action of the cannabinoids.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1324767     DOI: 10.1016/0006-8993(92)90222-u

Source DB:  PubMed          Journal:  Brain Res        ISSN: 0006-8993            Impact factor:   3.252


  14 in total

Review 1.  The endocannabinoid system and pain.

Authors:  Josée Guindon; Andrea G Hohmann
Journal:  CNS Neurol Disord Drug Targets       Date:  2009-12       Impact factor: 4.388

2.  Attenuation of morphine antinociceptive tolerance by cannabinoid CB1 and CB2 receptor antagonists.

Authors:  Ahmet Altun; Kemal Yildirim; Ercan Ozdemir; Ihsan Bagcivan; Sinan Gursoy; Nedim Durmus
Journal:  J Physiol Sci       Date:  2015-04-18       Impact factor: 2.781

3.  β-arrestin2 regulates cannabinoid CB1 receptor signaling and adaptation in a central nervous system region-dependent manner.

Authors:  Peter T Nguyen; Cullen L Schmid; Kirsten M Raehal; Dana E Selley; Laura M Bohn; Laura J Sim-Selley
Journal:  Biol Psychiatry       Date:  2012-01-20       Impact factor: 13.382

4.  Cannabinoid actions on rat superficial medullary dorsal horn neurons in vitro.

Authors:  E A Jennings; C W Vaughan; M J Christie
Journal:  J Physiol       Date:  2001-08-01       Impact factor: 5.182

5.  Cannabinoid potentiation of glycine receptors contributes to cannabis-induced analgesia.

Authors:  Wei Xiong; Kejun Cheng; Tanxing Cui; Grzegorz Godlewski; Kenner C Rice; Yan Xu; Li Zhang
Journal:  Nat Chem Biol       Date:  2011-04-03       Impact factor: 15.040

6.  Effects of alterations in cannabinoid signaling, alone and in combination with morphine, on pain-elicited and pain-suppressed behavior in mice.

Authors:  Laurence L Miller; Mitchell J Picker; Michael D Umberger; Karl T Schmidt; Linda A Dykstra
Journal:  J Pharmacol Exp Ther       Date:  2012-04-18       Impact factor: 4.030

7.  Suppression of noxious stimulus-evoked activity in the ventral posterolateral nucleus of the thalamus by a cannabinoid agonist: correlation between electrophysiological and antinociceptive effects.

Authors:  W J Martin; A G Hohmann; J M Walker
Journal:  J Neurosci       Date:  1996-10-15       Impact factor: 6.167

8.  Role of the cannabinoid system in pain control and therapeutic implications for the management of acute and chronic pain episodes.

Authors:  J Manzanares; Md Julian; A Carrascosa
Journal:  Curr Neuropharmacol       Date:  2006-07       Impact factor: 7.363

9.  c-Jun N terminal kinase signaling pathways mediate cannabinoid tolerance in an agonist-specific manner.

Authors:  Angela N Henderson-Redmond; Caitlin M Nealon; Brian J Davis; Matthew B Yuill; Diana E Sepulveda; Henry L Blanton; Mary K Piscura; Michael L Zee; Chris P Haskins; David J Marcus; Ken Mackie; Josée Guindon; Daniel J Morgan
Journal:  Neuropharmacology       Date:  2019-11-20       Impact factor: 5.250

10.  Different forms of glycine- and GABA(A)-receptor mediated inhibitory synaptic transmission in mouse superficial and deep dorsal horn neurons.

Authors:  Wayne B Anderson; Brett A Graham; Natalie J Beveridge; Paul A Tooney; Alan M Brichta; Robert J Callister
Journal:  Mol Pain       Date:  2009-11-18       Impact factor: 3.395

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.